Studies

Showing 121 studies.

A5257: Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers

DAIDS Number

Research Area

Antiretroviral Strategies

Study Status

Participants Off Study and Primary Analysis Completed

Locality

A5241: Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US

DAIDS Number

Research Area

Antiretroviral Strategies

Study Status

Locality

IMPAACT 2040: Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Virally Suppressed People with HIV-1 during Pregnancy and Postpartum

DAIDS Number

Research Area

Study Status

IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1

DAIDS Number

Research Area

Study Status

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Pharmacokinetics, and antiviral activity of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed HIV-Infected Children >2 to <12 years of age and weighing >10 kgs and <50 kgs

DAIDS Number

Research Area

Study Status

IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP)

DAIDS Number

Research Area

Study Status

IMPAACT 2034: Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

Research Area

Study Status

IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States

DAIDS Number

Research Area

Study Status

Closed to Follow Up

IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV

DAIDS Number

Research Area

Study Status

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

Research Area

Study Status